Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib with SRS in BRAF Mutant Melanoma Brain Metastases
NCT01721603Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Apr 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by University of California, San Francisco. Primary endpoint: Distant Brain Metastasis-free Survival at 6 months. Started Apr 2013; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01721603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721603.